DDInter1042 DDInter1476
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
Pirbuterol {u} (Compound) binds {v} (Gene) ADRB1
Pirbuterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Pirbuterol {u} (Compound) causes {v} (Side Effect) Dry mouth
Pirbuterol (Compound) resembles Bupranolol (Compound)
Pirbuterol (Compound) resembles Terbutaline (Compound)
Pirbuterol (Compound) treats asthma (Disease)
Pirbuterol (Compound) binds ADRB1 (Gene)
Pirbuterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Pirbuterol (Compound) causes Dry mouth (Side Effect)